Balu RB, Raffanti s, Wesolowski L, Justice AC, Fusco JS, Mangialardi W, Fusco GP. Sex specific differences in liver function and disease progression. Poster. 7th International Workshop on HIV Databases. March 2003, Fiuggi, Italy
Research Category: Abstracts and Posters
Comparison of HIV-1 protease inhibitor susceptibility results in viremic protease inhibitor(PI)-experienced patient samples analyzed by phenotyping and by five resistance algorithms
Paulsen D, Florance A, Liao Q, Boulme R, Shaefer M, Fusco GP, Ross L. Comparison of HIV-1 protease inhibitor susceptibility results in viremic protease inhibitor(PI)-experienced patient samples analyzed by phenotyping and by five resistance algorithms. Poster. 6th International HIV Drug Resistance Workshop. July 2002, Seville, Spain
Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy
Chene C, May M, Costagliola D, d’Arminio Monforte A, Junghans C, de Wolf F, Lundgren JD, Fusco GP, Miller V, Leport C, Dabis F, Hogg RS, Phillips AN, Gill MJ, Salzberger B, Sterne JAC, Egger M. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. Poster. XIV International AIDS Conference. July 2002, Barcelona, Spain
Low incidence of grade III/IV hepatotoxicity in first HAART: observations from 1100 patients followed for 1 year
Dieterich DT, Becker SL, Fusco JS, Balu RB, Most BM, Stern JAC, Lanes S, Fusco GP. Low incidence of grade III/IV hepatotoxicity in first HAART: observations from 1100 patients followed for 1 year. Poster. 4534. XIV International AIDS Conference. July 2002, Barcelona, Spain.
Strategies for obtaining consistent diagnoses for cause of death in an HIV observational cohort study
Fusco GP, Justice AC, Becker SL, Raffanti SP, Coll-Erickson P, Fusco JS. Strategies for obtaining consistent diagnoses for cause of death in an HIV observational cohort study. Poster. 5584. XIV International AIDS Conference. July 2002, Barcelona, Spain
Genotypic and phenotypic resistance patterns to Lopinavir and Amprenavir in viremic protease inhibitor-experienced patients
Ross L, Paulsen D, Liao Q, Fusco GP, Shaefer M, St. Clair M. Genotypic and phenotypic resistance patterns to Lopinavir and Amprenavir in viremic protease inhibitor-experienced patients. Poster. 4th International HIV Workshop on Management of Treatment-Experienced Patients. April 2001, Chicago, IL
What is the prognostic value of baseline CD4 cell count and viral load six months after initiating potent antiretroviral therapy?
Sterne JAS, Grabar S, d’Arminio Monforte A, Rickenbach M, de Wolf F, Lundgren JD, Fusco JS, Miller V, Raffi F, Dabis F, Hogg RS, Lampe F, Gill MJ, Salzberger B, May M, Egger M. What is the prognostic value of baseline CD4 cell count and viral load six months after initiating potent antiretroviral therapy? ART cohort collaboration. Poster. XIV International AIDS Conference. July 2002, Barcelona, Spain
Efficacy of amprenavir-containing HAART regimens in protease inhibitor-experience patient
Becker SL, Scarsella AJ, Chulay J, Fusco GP. Efficacy of amprenavir-containing HAART regimens in protease inhibitor-experience patients. Poster. 39th Annual Meeting of the Infectious Disease Society of America (IDSA). October 2001, San Francisco, CA
Predictors of virologic and immunologic success post treatment interruption (TI) in patients with chronic HIV infection
Braun JF, Fusco JS, Justice AC, Most BM, Fusco GP. Predictors of virologic and immunologic success post treatment interruption (TI) in patients with chronic HIV infection. Poster. 1909. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December 15-19, 2001, Chicago, IL
Clinical experience of lopinavir / ritonavir (LPV/RTV) following amprenavir (APV) use
Becker SL, Dieterich DT, Fusco GP. Clinical experience of lopinavir / ritonavir (LPV/RTV) following amprenavir (APV) use. Poster. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. October 2001, Athens, Greece.